WHO option B+: early experience of antiretroviral therapy sequencing after cessation of breastfeeding and risk of dermatologic toxicity

J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):e101-3. doi: 10.1097/QAI.0b013e31828011ca.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Anti-Retroviral Agents / adverse effects*
  • Benzoxazines / administration & dosage
  • Benzoxazines / adverse effects
  • Breast Feeding
  • CD4 Lymphocyte Count
  • Cohort Studies
  • Dideoxynucleosides / administration & dosage
  • Dideoxynucleosides / adverse effects
  • Drug Eruptions / etiology*
  • Drug Substitution / adverse effects*
  • Female
  • HIV Infections / prevention & control*
  • HIV Infections / transmission
  • Humans
  • Infectious Disease Transmission, Vertical / prevention & control
  • Lopinavir / administration & dosage
  • Lopinavir / adverse effects
  • Nevirapine / administration & dosage
  • Nevirapine / adverse effects
  • Pregnancy
  • Pregnancy Complications, Infectious / drug therapy
  • Pregnancy Complications, Infectious / virology
  • Protease Inhibitors / adverse effects*
  • Ritonavir / administration & dosage
  • Ritonavir / adverse effects
  • Uganda
  • World Health Organization

Substances

  • Anti-Retroviral Agents
  • Benzoxazines
  • Dideoxynucleosides
  • Protease Inhibitors
  • Lopinavir
  • Nevirapine
  • efavirenz
  • Ritonavir
  • abacavir

Associated data

  • ClinicalTrials.gov/NCT00993031